Navigation Links
Results of the NEXT clinical trial Reported at TCT 2011
Date:11/11/2011

SAN FRANCISCO, CA NOVEMBER 11, 2011 Researchers have found that polymer-free amphilimus-eluting stents in de novo coronary artery lesions showed a significantly lower in-stent late loss at six months compared to paclitaxel-eluting stents with permanent polymers.

Results of the NEXT trial were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. NEXT is a prospective, randomized trial comparing a polymer-free amphilimus-eluting stent to a paclitaxel-eluting stent.

The risk/benefit balance of coronary drug-eluting stents is still suboptimal, and the safety of coating polymers, which hold and release the drug over time, remains uncertain. Researchers sought to demonstrate the non-inferiority of polymer-free amphilimus-eluting stents versus permanent-polymer paclitaxel-eluting stents in de novo native coronary artery lesions. The primary endpoint was six-month angiographic in-stent late loss within a non-inferiority scope. Late loss is the difference between the diameter of a stented segment post-procedure compared with the follow-up angiogram.

A total of 323 patients were enrolled, with 162 randomized to amphilimus-eluting stents and 161 to paclitaxel-eluting stents. In-stent late loss was significantly lower with amphilimus-eluting stents (0.140.36 mm vs. 0.340.40 mm, P<0.0001 for non-inferiority, P<0.0001 for superiority). Clinical endpoints (cardiac death, myocardial infarction, target lesion revascularization or stent thrombosis) up to 12 months did not differ significantly.

"These results are encouraging evidence that support the use of polymer-free stents, but further studies are warranted to prove that this potent polymer-free stent can improve the risk-benefit balance of coronary drug-eluting stents," said Didier Carri, MD, PhD, the principal investigator of the trial. Dr. Carri is Professor of Medicine, Cardiology at the University of Paul Sabatier and the Head of Hemodynamics and Angioplasty Section at Rangueil Hospital in Toulouse, France.


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Results of the PEPCAD-DES trial reported at TCT 2011
2. Results of the STACCATO Trial reported at TCT 2011
3. Results of the DEB-AMI Trial reported at TCT 2011
4. Results of the RIFLE STEACS clinical trial reported at TCT 2011
5. Results of the PARTNER Trial Cohort B 2-year follow up presented at TCT 2011
6. Results of the PARTNER Trial Cohort A cost effectiveness analysis reported
7. Combination epigenetic therapy clinical trial results
8. Results of the PARIS registry Reported at TCT 2011
9. Results of the TRIGGER-PCI trial reported at TCT 2011
10. Results of rapid gene trial reported at TCT 2011
11. Results of the BRIDGE trial reported at TCT 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... , ... June 28, 2017 , ... Quorum Health announced ... Resources (QHR). At the same time, John Maher was promoted to COO of QHR. ... the retirement of Mickey Bilbrey, former president and CEO in December 2016. ...
(Date:6/28/2017)... ... June 28, 2017 , ... Guide to FDA and EU Medical Device ... on which side of the Atlantic devicemakers do business, this fully updated and expanded ... , In addition to the full text of the FDA’s regulations in 21 CFR ...
(Date:6/28/2017)... Orland Park, IL (PRWEB) , ... June 28, 2017 , ... David B. Sosin, ... in Orland Park, Illinois, took over the post of 2nd Vice President for the ... , Sosin was installed as the ISBA’s 3rd Vice President in 2016 following a state-wide ...
(Date:6/28/2017)... ... June 28, 2017 , ... Canadian Zeolite Corp. (the “Company”) ... year study conducted by the University of Saskatchewan in partnership with PotashCorp, Agrium ... brine-impacted groundwater. As a part of the study, batch adsorption experiments were conducted ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... consulting firm servicing communities throughout the greater Cincinnati metropolitan area, is teaming up ... temporary lodgings for families with children receiving treatment in nearby hospitals. , Ronald ...
Breaking Medicine News(10 mins):
(Date:6/20/2017)... HILLS, Calif. , June 20, 2017 SkylineDx ... the use of MMprofiler with SKY92, the company,s prognostic ... In a poster presentation at the 22 nd ... Madrid, Spain , SkylineDx researchers will demonstrate ... patients. In a separate e-poster presentation ...
(Date:6/16/2017)... 2017  Exactly 50 years ago today, the Monterey Pop ... known as the San Francisco "Summer of Love."  To celebrate ... radical innovations in strategic market research portals that it will ... beginning of Northern Light,s "Summer of Love (For Our Customers)."  ... ...
(Date:6/13/2017)... , June 13, 2017 Zimmer Biomet Holdings, ... healthcare, today announced that the U.S. Food and Drug Administration ... June 3, 2015 relating to its Zhejiang, China ... "The successful clearance of the Warning ... manufacturing facility is a measure of the progress we ...
Breaking Medicine Technology: